Søndergaard, Anette Luther
Novo Nordisk (Denmark)
3 papers on CoChat
Most cited papers
- Verified
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 463
- Verified
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 188
- Verified
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
Koren, M. J., Descamps, O., Hata, Y., Hengeveld, E. M., Hovingh, G. K., Ikonomidis, I., Radu Juul Jensen, M. D., Langbakke, I. H., Martens, F. M. A. C., Søndergaard, A. L., et al. (2024) · The Lancet Diabetes & Endocrinology
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 43
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free